Watch an on-demand, CPE-certified Webcast and download slidesets from our live symposia at AMCP 2018 and AMCP Nexus 2018 where our pharmacy and oncology experts reviewed the rationale for checkpoint inhibitor therapy in unresectable stage III NSCLC, how to optimally integrate checkpoint inhibitors into this setting, and strategies for identifying and managing immune-related adverse events.
In this downloadable slideset, Ali McBride PharmD, MS, BCOP, FAzPA, explores the underlying rationale for immune checkpoint inhibitor therapy in the care of patients with stage III NSCLC.
In this downloadable slideset, Mark M. Awad, MD, PhD, and Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, juxtapose historical data for concurrent CRT with new evidence for immune checkpoint therapy in the care of patients with stage III NSCLC.
In this downloadable slideset, Sandra Cuellar, PharmD, BCOP, reviews pharmacy perspectives in the assessment and management of adverse events associated with immune checkpoint therapy in the care of patients with stage III NSCLC.
Watch this CPE-certified Webcast of a CCO symposium at AMCP 2018, where Mark M. Awad, MD, PhD; Sandra Cuellar, PharmD, BCOP; and Ali McBride, PharmD, MS, BCOP, FAzPA, review and discuss the latest data on immune checkpoint inhibitors for stage III NSCLC as they apply to pharmacists and managed care professionals.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.